Pulmonary arterial hypertension in a patient treated with dasatinib : A case report

Simple item page
dc.contributor.authorSkride, Andris
dc.contributor.authorSablinskis, Matiss
dc.contributor.authorSablinskis, Kristaps
dc.contributor.authorLesina, Krista
dc.contributor.authorLejnieks, Aivars
dc.contributor.authorLejniece, Sandra
dc.contributor.institutionRīga Stradiņš University
dc.date.accessioned2021-05-18T13:40:01Z
dc.date.available2021-05-18T13:40:01Z
dc.date.issued2017-12-29
dc.descriptionPublisher Copyright: © 2017 The Author(s).
dc.description.abstractBackground: There have been several reports on dasatinib-induced reversible pulmonary hypertension. This is the first reported case in Latvia; the patient did not discontinue the drug after the first adverse effects in the form of pleural effusions, which we speculate led only to partial reversion of the disease. Case presentation: A 67-year-old white man with chronic myelogenous leukemia was treated with the dual Src and BCR-ABL tyrosine kinase inhibitor dasatinib. After treatment with dasatinib he had multiple pleural effusions which were suspected to be caused by congestive heart failure. Later a transthoracic Doppler echocardiography and right-sided heart catheterization revealed severe pulmonary hypertension with pulmonary vascular resistance of 12 Wood units and mean pulmonary artery pressure of 53 mmHg. Computed tomography ruled out a possible pulmonary embolism; laboratory specific tests for human immunodeficiency virus, rheumatoid factor, and anti-nuclear antibodies were negative, and dasatinib-induced pulmonary arterial hypertension was diagnosed. A follow-up right-sided heart catheterization and 6-minute walk test done a month after the discontinuation of dasatinib showed significant improvement: mean pulmonary artery pressure of 34 mmHg and pulmonary vascular resistance of 4 Wood units. Conclusions: Patients should always be closely monitored when using dasatinib for a prolonged time. Dasatinib-induced pulmonary hypertension may be fully reversible after the therapy is suspended, but the key factors involved are still unclear and need to be further studied.en
dc.description.statusPeer reviewed
dc.format.extent341438
dc.identifier.citationSkride, A, Sablinskis, M, Sablinskis, K, Lesina, K, Lejnieks, A & Lejniece, S 2017, 'Pulmonary arterial hypertension in a patient treated with dasatinib : A case report', Journal of Medical Case Reports, vol. 11, no. 1, 362. https://doi.org/10.1186/s13256-017-1515-9
dc.identifier.doi10.1186/s13256-017-1515-9
dc.identifier.issn1752-1947
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/4363
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85039774379&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofJournal of Medical Case Reports
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectChronic myelogenous leukemia
dc.subjectDasatinib
dc.subjectPleural effusion
dc.subjectPulmonary arterial hypertension
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectGeneral Medicine
dc.subjectSDG 3 - Good Health and Well-being
dc.titlePulmonary arterial hypertension in a patient treated with dasatinib : A case reporten
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Pulmonary_arterial_hypertension.pdf
Size:
333.44 KB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure